158 related articles for article (PubMed ID: 34662129)
1. Intraperitoneal Administration of a Cisplatin-Loaded Nanogel through a Hybrid System Containing an Alginic Acid-Based Nanogel and an
Yamaguchi K; Hiraike O; Iwaki H; Matsumiya K; Nakamura N; Sone K; Ohta S; Osuga Y; Ito T
Mol Pharm; 2021 Nov; 18(11):4090-4098. PubMed ID: 34662129
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal Delivery of Cisplatin via a Hyaluronan-Based Nanogel/in Situ Cross-Linkable Hydrogel Hybrid System for Peritoneal Dissemination of Gastric Cancer.
Ohta S; Hiramoto S; Amano Y; Emoto S; Yamaguchi H; Ishigami H; Kitayama J; Ito T
Mol Pharm; 2017 Sep; 14(9):3105-3113. PubMed ID: 28806513
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer.
Emoto S; Yamaguchi H; Kamei T; Ishigami H; Suhara T; Suzuki Y; Ito T; Kitayama J; Watanabe T
Surg Today; 2014 May; 44(5):919-26. PubMed ID: 23887848
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.
Takakura M; Nakamura M; Kyo S; Hashimoto M; Mori N; Ikoma T; Mizumoto Y; Fujiwara T; Urata Y; Inoue M
Cancer Gene Ther; 2010 Jan; 17(1):11-9. PubMed ID: 19662088
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal chemotherapy for peritoneal metastases using sustained release formula of cisplatin-incorporated gelatin hydrogel granules.
Yamashita K; Tsunoda S; Gunji S; Murakami T; Suzuki T; Tabata Y; Sakai Y
Surg Today; 2019 Sep; 49(9):785-794. PubMed ID: 30847629
[TBL] [Abstract][Full Text] [Related]
6. pH-Responsive Fluorescence Enhanced Nanogel for Targeted Delivery of AUR and CDDP Against Breast Cancer.
Cao Z; Li W; Liu R; Li C; Song Y; Liu G; Chen Y; Lu C; Lu A; Liu Y
Int J Nanomedicine; 2020; 15():8369-8382. PubMed ID: 33149581
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of heparin-polyethyleneimine nanogels delivering claudin-3-targeted short hairpin RNA combined with low-dose cisplatin on ovarian cancer.
Liu L; Gou M; Yi T; Bai Y; Wei Y; Zhao X
Oncol Rep; 2014 Apr; 31(4):1623-8. PubMed ID: 24482188
[TBL] [Abstract][Full Text] [Related]
8. LHRH-targeted nanogels as a delivery system for cisplatin to ovarian cancer.
Nukolova NV; Oberoi HS; Zhao Y; Chekhonin VP; Kabanov AV; Bronich TK
Mol Pharm; 2013 Oct; 10(10):3913-21. PubMed ID: 23957812
[TBL] [Abstract][Full Text] [Related]
9. Controlled release of cisplatin from pH-thermal dual responsive nanogels.
Peng J; Qi T; Liao J; Chu B; Yang Q; Li W; Qu Y; Luo F; Qian Z
Biomaterials; 2013 Nov; 34(34):8726-40. PubMed ID: 23948167
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
[TBL] [Abstract][Full Text] [Related]
11. A novel intraperitoneal therapy for gastric cancer with DFP-10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model.
Ando H; Fukushima M; Eshima K; Hasui T; Shimizu T; Ishima Y; Huang CL; Wada H; Ishida T
Cancer Med; 2019 Dec; 8(17):7313-7321. PubMed ID: 31609087
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with paclitaxel and intraperitoneal cisplatin for ovarian cancer with disseminated lesions in the peritoneum and the diaphragm.
Terauchi F; Moritake T; Yamamoto Y; Ogura H
Int J Clin Oncol; 2002 Dec; 7(6):356-60. PubMed ID: 12494251
[TBL] [Abstract][Full Text] [Related]
13. The enhanced antitumor effects of biodegradable cationic heparin-polyethyleneimine nanogels delivering HSulf-1 gene combined with cisplatin on ovarian cancer.
Liu P; Gou M; Yi T; Qi X; Xie C; Zhou S; Deng H; Wei Y; Zhao X
Int J Oncol; 2012 Oct; 41(4):1504-12. PubMed ID: 22825572
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of platinum-taxane combination therapy in ovarian cancer.
Desale SS; Soni KS; Romanova S; Cohen SM; Bronich TK
J Control Release; 2015 Dec; 220(Pt B):651-9. PubMed ID: 26381902
[TBL] [Abstract][Full Text] [Related]
15. Development of a hybrid dextrin hydrogel encapsulating dextrin nanogel as protein delivery system.
Molinos M; Carvalho V; Silva DM; Gama FM
Biomacromolecules; 2012 Feb; 13(2):517-27. PubMed ID: 22288730
[TBL] [Abstract][Full Text] [Related]
16. A novel drug delivery system of intraperitoneal chemotherapy for peritoneal carcinomatosis using gelatin microspheres incorporating cisplatin.
Gunji S; Obama K; Matsui M; Tabata Y; Sakai Y
Surgery; 2013 Nov; 154(5):991-9. PubMed ID: 24008088
[TBL] [Abstract][Full Text] [Related]
17. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer.
Sugiyama T; Kumagai S; Nishida T; Ushijima K; Matsuo T; Yakushiji M; Hyon SH; Ikada Y
Anticancer Res; 1998; 18(4B):2837-42. PubMed ID: 9713471
[TBL] [Abstract][Full Text] [Related]
18. Efficient inhibition of ovarian cancer by recombinant CXC chemokine ligand 10 delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels.
Yang F; Gou M; Deng H; Yi T; Zhong Q; Wei Y; Zhao X
Oncol Rep; 2012 Aug; 28(2):668-76. PubMed ID: 22684947
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment.
Baldwin P; Ohman AW; Tangutoori S; Dinulescu DM; Sridhar S
Int J Nanomedicine; 2018; 13():8063-8074. PubMed ID: 30555227
[TBL] [Abstract][Full Text] [Related]
20. Double-crosslinked nanocomposite hydrogels for temporal control of drug dosing in combination therapy.
Wu C; Liu J; Zhai Z; Yang L; Tang X; Zhao L; Xu K; Zhong W
Acta Biomater; 2020 Apr; 106():278-288. PubMed ID: 32084599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
